light/dark cycle at 21°C, with free access to food and water until the time of surgery; after surgery they were housed individually. Chronic indwelling cannulae were implanted into the jugular vein and carotid artery to allow simultaneous venous infusion of drug solutions and sampling of arterial blood as described previously. 3 
Drugs
Ketamine hydrochloride (KetalarÔ, Parke-Davis Australia Pty Ltd, Sydney, Australia) was diluted to a concentration of 20 mg ml ±1 (17.3 mg ml ±1 as base); alfentanil hydrochloride (RapifenÔ, Astra-Zeneca Australia Pty Ltd, Sydney, Australia) was diluted to a concentration of 100 mg ml ±1 (92 mg ml ±1 as base). Both drug solutions were diluted with de-ionized water; alfentanil contained 5 units ml ±1 heparin.
Experimental design
Studies were performed in three groups of animals 24 h after cannulation, and were carried out between 14:00 and 19:00 h. Infusion and sampling lines (75 and 45 cm, respectively) were attached to the venous and arterial indwelling cannulae, and the animals were placed in a study chamber and allowed to settle for 30 min before commencement of the study. The relevant drug infusions (see below) were delivered by a syringe driver (Harvard Apparatus, Model 22) from a gas tight syringe (Hamilton, 5 ml). In groups 1 and 3 (described below), immediately after loss of righting re¯ex, the animals were removed from the study chamber, a rectal thermal probe was inserted, and body temperature was maintained by a heating lamp; no loss of righting re¯ex occurred in group 2. Once motor function began to return the rectal probe was removed and the animals were returned to the study chamber. Arterial blood samples (100 ml) were collected into heparinized (50 units) 1.5 ml polyethylene microfuge tubes for drug analysis; these were replaced with 3 volumes of 0.9% saline as described previously. 3 After the ®nal blood sample was collected, the animals were killed by carbon dioxide asphyxiation. Central nervous system (CNS=regional brain and spinal cord), heart, lung, liver, kidney, gut, adductor muscle, and epididymal fat pad tissues were sampled for the determination of tissue:plasma drug distribution. The tissue: plasma distribution coef®cients of ketamine and alfentanil were determined after each of the following infusion paradigms. Group 1. An infusion of ketamine was administered at a constant rate of 10 mg kg ±1 min ±1 over 5 min; serial arterial blood samples were taken before, then at 1.5, 3, 5, 7, 10, 15, 20, 30, 40, 60, 80, 100, 120, 140, 160 , and 180 min after commencement of the infusion. Group 2. An infusion of alfentanil, computer-controlled by Stanpump software, 4 was used to maintain a constant plasma concentration of alfentanil (target value of 100 mg ml ±1 ) that would be antinociceptive, without causing signi®cant ventilatory impairment or EEG changes, based on previous animal experiments. 5±8 Pharmacokinetic parameters, describing a three-compartment mamillary model, were obtained from previously published data 9 and used to implement the infusion algorithm. Serial arterial blood samples were collected before, then at 1.5, 3, 5, 10, 20, 40, 60, 80, 100, 120, 140, 160, and 180 min for the duration of the infusion. Group 3. An infusion of ketamine was administered over 5 min as in group 1, the infusion line for ketamine was then removed and a new infusion line primed with alfentanil was attached; 7 min later (i.e. at 12 min after the start of the ketamine infusion), alfentanil was delivered by the Stanpump infusion paradigm as in group 2. Blood samples were collected as before in group 1: the ®rst blood sample to contain alfentanil was taken at 15 min (i.e. 3 min after commencement of the alfentanil infusion). Ketamine and alfentanil plasma concentrations were measured in the same blood samples.
Analytical procedures
In group 1, concentrations of ketamine and norketamine were measured as the sum of individual R(±)-and S(+)-ketamine enantiomer concentrations determined by HPLC following chiral separation on a micro chiral-AGP column. 10 This method was not suitable for the concurrent determination of ketamine and alfentanil in groups 2 and 3, due to marked differences in their chromatographic characteristics on this column type and inadequate sensitivity for the determination of alfentanil concentrations. In these groups the plasma and tissue concentrations of alfentanil, ketamine, and norketamine were determined by adaptation of previously published gas chromatography-mass spectrometry (GC-MS) procedures, 11 12 as described below. Plasma. After the addition of cyproheptadine (50 ml, 1 mg ml ±1 , internal standard) and Na 3 PO 4 (100 ml, 0.5 M), aliquots of plasma (50 ml) in polypropylene tubes (1.5 ml) were brie¯y vortex-mixed, then extracted by shaking (5 min) with cyclohexane containing iso-amyl alcohol (1 ml, 2% v.v ±1 ). Tubes were centrifuged (3000 r.p.m., 5 min) and the organic phase transferred to a fresh polypropylene tube (1.5 ml) with a Pasteur pipette, dried in a bench rotatory vacuum centrifuge, reconstituted in toluene (100 ml), and transferred to polypropylene inserts immediately before analysis. Tissues. Homogenates of tissue (100 mg ml ±1 ) in NaH 2 PO 4 (100 mM) were frozen and resuspended after thawing immediately before analysis. Aliquots of homogenate (1 ml) were transferred to polypropylene tubes (10 ml), before the addition of cyproheptadine (100 ml, 1 mg ml ±1 , internal standard) and NaOH (250 ml, 1 M). The tubes were brie¯y vortex-mixed, then extracted by shaking (5 min) with cyclohexane containing iso-amyl alcohol (3 ml, 2% v.v ±1 ). After centrifugation (3000 r.p.m., 5 min), the organic phase was transferred to a fresh polypropylene tube (10 ml) with a Pasteur pipette, and HCl (400 ml, 0.5 M) was added. Tubes were shaken (5 min) and centrifuged as before, the organic phase was decanted and discarded, and NaOH (60 ml, 5 M) was added. After brief vortex mixing, cyclohexane containing iso-amyl alcohol (1 ml, 2% v.v ±1 ) was added and the tubes shaken and centrifuged as before. The organic phase was transferred to a polypropylene tube (1.5 ml) with a Pasteur pipette, dried in a bench rotatory vacuum centrifuge, reconstituted in toluene (100 ml), and transferred to polypropylene inserts immediately before analysis. GC-MS methodology. Toluene extracts were analysed on a Hewlett Packard 5972 MS/5890 Group II GC system, operating in electron impact mode (70 eV), after split-less injection onto a capillary column (HP-5MS, 30 m length Q 0.25 mm ID, 0.25-mm ®lm thickness). The oven temperature was held at 110°C initially for 0.5 min then increased at 25°C min ±1 to 280°C, while the injector and transfer lines were maintained at 280°C. Helium was used as the carrier gas at a¯ow rate of 1 ml min ±1 . A run time of 10 min and an injection volume of 1 ml were used for the analysis of ketamine and norketamine, while for alfentanil a run time of 15 min and an injection volume of 5 ml was used. Mass fragments (and retention times) for ketamine and norketamine were monitored with a dwell time of 50 ms at m/z 180 (6.1 min) and m/z 166 (6.0 min), respectively; alfentanil and cyproheptadine were monitored with a dwell time of 100 ms at m/z 289 (12.7 min) and m/z 287 (8.2 min), respectively.
Data analysis
Area under the curve (AUC) values for each plasma concentration±time data set were determined by the linear trapezoid method. Distribution coef®cients were calculated as the ratio of tissue to plasma analyte concentrations, uncorrected for residual tissue blood volume. Between group comparisons of the tissue distribution coef®cients for ketamine and norketamine were performed on log-transformed values, and the antilogs of the mean log-transformed values were subsequently referred to as the log-normalized values of the distribution coef®cients. Regional CNS tissue drug concentrations and distribution coef®cients were compared by one-way analysis of variance (ANOVA); individual post-hoc comparisons between mean values were performed by the method of Least Signi®cant Difference (Statistix for Windowsâ, Analytical Software, Tallahassee, FL, USA). Tissue drug concentrations and distribution coef®cients between the two infusion paradigms were compared by Student's two sample t-tests. The pharmacokinetic parameters for ketamine were determined by ®tting polyexponential decay equations to the concentration±time washout curve, and the mean total body clearance (Cl T ), initial dilution volume (V C ), volume of distribution at steady state (V SS ), terminal half-life (t 1/2 ), and mean residence time in the body (MRT) were calculated by conventional means. 13 Data are expressed as mean (SEM) unless speci®ed otherwise.
Results
Ketamine and norketamine concentrations in arterial plasma following infusion in groups 1 and 3 are compared in Figure  1 . The mean value of ketamine AUC for group 1 (ketamine alone=429 (7) mg min ml ±1 ) was signi®cantly greater (P=0.031) than the value for group 3 (ketamine followed by alfentanil=372 (21) mg min ml ±1 ). Similarly, the mean value of the AUC for norketamine was also signi®cantly greater (P=0.038) in group 1 (199 (16) mg min ml ±1 ) than for group 3 (150 (14) mg min ml ±1 ) due, mainly, to the plasma norketamine concentrations being signi®cantly different (P<0.05) between 7 and 90 min. The pharmacokinetic parameters for ketamine following infusions in groups 1 and 3 are given in Table 1 . Both clearance (Cl T ) and volume of distribution at steady state (V SS ) were signi®cantly greater ±1 min ±1 over 5 min, alone (n=9) or when followed 12 min later, by Stanpump-controlled alfentanil infusion (n=8) until conclusion of the study at 180 min. 31 (1) 30 (1) Edwards et al.
for ketamine when the alfentanil infusion followed the ketamine infusion (P<0.05). Ketamine tissue concentrations and distribution coef®-cients at the conclusion of serial blood sampling in groups 1 and 3 are shown in Tables 2 and 3 . Regional differences in CNS ketamine concentrations were not signi®cant in group 1 but were apparent in group 3 (F 2,21 =6.78, P=0.005; hindbrain > spinal cord: P=0.025; hindbrain > forebrain: P=0.002). Similarly, there were signi®cant differences in regional CNS norketamine concentrations in group 3 (F 2,21 =4.27, P=0.028; hindbrain > forebrain: P=0.02). In group 1, norketamine enantiomer concentrations in the CNS and myocardium were lower than the limit of (spectrophotometric) quantitation following HPLC-chiral separation. Ketamine CNS tissue concentrations were signi®cantly higher in forebrain (P<0.05) and hindbrain (P<0.01) following infusions in group 3 than in group 1; the corresponding log-transformed distribution coef®cients were also signi®cantly higher for forebrain (P<0.005) and hindbrain (P<0.01). Log-transformed CNS distribution coef®cients for ketamine in group 1 did not differ regionally. In group 3, signi®cant regional CNS differences were
Ketamine concentrations in the lungs were signi®cantly lower in group 3 than in group 1 (P<0.05), but those in the gut (P<0.05) and fat (P<0.001) were signi®cantly higher; the corresponding log-transformed distribution coef®cients were also signi®cantly lower in the lungs (P<0.05) and signi®cantly higher in gut (P<0.005) and fat (P<0.001). Norketamine concentrations were signi®cantly higher in liver (P<0.001), kidney (P<0.005), gut (P<0.001), and fat (P<0.001) following infusions in group 3, than in group 1, but the corresponding log-transformed distribution coef®-cients for these tissues were not signi®cantly different.
Alfentanil arterial plasma concentrations from the Stanpump-controlled infusions in group 2 and 3 animals are shown in Figure 2 . In group 2 animals, where alfentanil infusion was given alone, the animals displayed episodic sleep-like behaviour, but did not demonstrate other potential alfentanil-induced effects such as loss of righting re¯ex, ataxia, increased muscle tone, or convulsions. The mean AUC value from 20 to 180 min for alfentanil was not signi®cantly different between the infusions in group 2 Table 3 Log-normalized mean (and 95% con®dence limits) tissue:plasma distribution coef®cients (uncorrected for residual blood volume) for ketamine (Ket) and norketamine (Nket) in rats after initial infusion of ketamine at 10 mg kg ±1 min ±1 over 5 min, alone or when followed 12 min later, by Stanpumpcontrolled alfentanil (Alf) infusion until conclusion of the study at 180 min. Sample numbers are given in parentheses (n (7625 (134) ng min ml ±1 ) and group 3 (7194 (634) ng min ml ±1 ), but plasma alfentanil concentrations were signi®-cantly lower (P=0.0012) at 20 min in group 3. Tissue concentrations of alfentanil at 180 min following infusions in groups 2 and 3 are shown in Table 4 . Signi®cant regional differences in CNS alfentanil concentrations were apparent in both group 2 (F 2,21 =22.76, P<0.0001; forebrain > hindbrain and spinal cord: P=0.001) and group 3 (F 2,21 =6.48, P=0.0064; forebrain < hindbrain and spinal cord: P=0.02). Concentrations of alfentanil were signi®-cantly lower in forebrain (P<0.0001) and hindbrain (P<0.01), when alfentanil infusion followed ketamine administration. Similarly, there were signi®cant differences in the corresponding regional CNS distribution coef®cients following alfentanil infusions in both group 2 (F 2,21 =19.28, P<0.0001; forebrain > hindbrain and spinal cord: P=0.001) and group 3 (F 2,21 =4.45, P=0.024; forebrain < hindbrain and spinal cord: P=0.05). Alfentanil distribution coef®cient for the forebrain was signi®cantly lower (P<0.0001) when alfentanil infusion followed ketamine administration. Although concentrations of alfentanil were signi®cantly lower in heart (P<0.01), lung (P<0.0001), and gut (P<0.0001) following infusions in group 3, the corresponding distribution coef®cients did not differ signi®cantly.
Discussion
Ketamine, a phencyclidine (PCP) analogue, acts as a noncompetitive inhibitor of the N-methyl-D-aspartate (NMDA) receptor in the CNS by binding to the PCP recognition site in the NMDA receptor ion-channel complex.
14 Analgesic effects associated with subanaesthetic doses of ketamine appear to be mediated by this non-opioid PCP receptor mechanism in both experimental and postoperative pain. 15 16 Additionally, laboratory studies have found the primary metabolite of ketamine, norketamine, also to have antinociceptive properties, 17 potentially augmenting those of the parent drug. Furthermore, both ketamine and norketamine have been found to inhibit NMDA receptor function stereoselectively. 18 Alfentanil has a very short duration of action following a brief duration of infusion, mainly due to its weak tissue binding. 19 Although there is evidence for alfentanil to exert a longer half-life and duration of effect with longer durations of infusion, 20±22 it is well-suited to i.v. infusion delivery, especially for intraoperative analgesia in surgical patients. Opioids such as alfentanil reproducibly modify the quantitative electroencephalogram (EEG), especially in the delta (0.5±4.5 Hz) frequency band. Alfentanil plasma concentrations used in the present study were in the range reported as having little to no direct EEG effect. Other studies on antinociceptive effects of alfentanil have found an EC 50 of 24 ng ml ±1 for suppression of tooth pulp evoked potential (TPEP) changes in the EEG. 8 Thus, the present study used alfentanil plasma concentrations within the antinociceptive range, but lower than values associated with signi®cant direct EEG changes (EC 50 approximately 200 ng ml ±1 ). 5 7 Mean values for ketamine Cl T and V SS (Table 1) were consistent with values reported by others; 23 however, the signi®cantly lower plasma ketamine concentration±time AUC values for group 3 compared with group 1 animals re¯ect the greater Cl T and V SS for ketamine during alfentanil infusion. Arterial blood pH and PCO 2 were not measured in this study but, for several reasons, we believe that a ventilatory depressant effect of alfentanil was unlikely to account for this difference. There were no obvious effects of alfentanil in animals when alfentanil infusions were given alone. Plasma alfentanil concentrations less than 100 ng ml ±1 have previously been shown to have no effect on arterial PCO 2 .
8 Moreover, as the pKa of ketamine is 7.5, 24 a decreased arterial blood pH due to ventilatory depression would increase the ionized state fraction of ketamine, thereby retarding its extravascular distribution and resulting in lower values for V SS and possibly Cl T . Similarly, cardiovascular differences between the two groups are also unlikely to account for the different pharmacokinetic values for ketamine in the presence of alfentanil. Attenuation by alfentanil of ketamine's sympathomimeticcardiovascular effects could also be expected to retard distribution and reduce V SS and possibly Cl T . Both the V SS and Cl T of ketamine; however, were signi®cantly increased in the presence of alfentanil.
Alfentanil appeared to facilitate the uptake of ketamine into both gut and adipose tissue. Opioids tend to reduce sympathetic tone and enhance parasympathetic tone. These effects, along with a possible direct vascular effect, can result in dilation of arterial and venous vascular beds, 25 and possibly account for the greater uptake into gut and adipose tissue, and the higher clearance, found for ketamine in the presence of alfentanil infusion. In the lung, however, tissue uptake of ketamine was less suggesting that, following i.v. infusion of alfentanil, high local concentrations of alfentanil may have displaced ketamine from tissue binding sites. This suggestion is consistent with the known higher af®nity of alfentanil than ketamine for plasma proteins, 23 the high degree of ketamine uptake into the lungs, 26 and saturability of binding of such basic drugs in lung tissue. 27 Tissue norketamine concentrations were signi®cantly higher in liver (52%), kidney (40%), and gut (53%), when ketamine infusion was followed by alfentanil. The lack of signi®cant difference in the corresponding distribution coef®cients for norketamine in these tissues most likely re¯ects signi®cant local metabolism of ketamine to norketamine in these tissues. 10 Signi®cantly higher concentrations of norketamine in adipose tissue, however, probably re¯ects redistribution from the gut, as local metabolic conversion of ketamine to norketamine would be unlikely. However, the mean AUC value for norketamine was signi®cantly higher (by 25%) in group 1 than group 3 due, mainly, to signi®cant divergence in plasma norketamine concentrations from 7 (to 90) min, 2 min after cessation of the ketamine infusion (alfentanil infusions in group 3 did not begin until 12 min after the ketamine infusion had commenced). Norketamine in group 1 samples was quanti®ed by spectrophotometric detection following chiral stationary phase HPLC separation, but in group 3 norketamine was quanti®ed by the more speci®c technique of massselective detection following gas chromatographic separation. Norketamine, after its formation from ketamine by Ndemethylation, may undergo further oxidative metabolism to 6-hydroxynorketamine. 28 It is possible that such an additional metabolite contributed to the AUC values for plasma norketamine in group 1, because norketamine concentrations in liver, kidney, and gut (the tissues that contributed to circulating norketamine concentrations) were in fact higher in group 3.
Plasma alfentanil concentrations were signi®cantly lower at 20 min when Stanpump-controlled alfentanil infusion followed ketamine infusion. Ketamine concentrations in plasma were three orders of magnitude higher than those of alfentanil, and competitive displacement from plasma protein binding sites may have facilitated tissue uptake in the early stages of the alfentanil infusion. 23 The subsequent redistribution of ketamine into more poorly perfused tissues appeared to offset the initial facilitated tissue uptake of alfentanil following ketamine infusion. Although tissue concentrations of alfentanil were signi®cantly lower in heart, lung, and gut, when alfentanil infusion followed ketamine administration, the distribution coef®cients indicated that tissue uptake of alfentanil by these tissues was not affected by ketamine infusion.
In the CNS, tissue uptake of ketamine into both the forebrain and hindbrain was signi®cantly greater in the presence of alfentanil, although ketamine signi®cantly reduced tissue uptake of alfentanil into the forebrain, possibly suggesting local competitive displacement of alfentanil by ketamine from tissue binding sites. Recently, ketamine has been found to exert analgesic effects supraspinally, through activation of inhibitory monoaminergic pathways descending to the spinal cord, and antihyperalgesic effects at the level of the spinal cord through inhibition of NMDA receptor function. 29 Moreover, opioids also exert analgesic effects through activation of monoaminergic pathways that originate in the brain stem and descend to the spinal cord. 30 Plasma alfentanil concentrations of approximately 50 ng ml ±1 , maintained over the duration of this investigation, were approximately double the EC 50 found for suppression of TPEP 8 and therefore likely to be associated with analgesia. Others have reported that ketamine allays the development of antinociceptive tolerance to alfentanil. 31 This ®nding that the distribution of ketamine into the brain was increased by constant low plasma concentrations of alfentanil could therefore have implications for the interpretation of such pharmacological studies and have important clinical applications for pain management.
